STOCK TITAN
  1. Home
  2. News
  3. IMNM

Immunome, Inc. - IMNM STOCK NEWS

Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.

Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.

The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.

Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.

The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.

News

Immunome Appoints Sandra M. Swain to Board of Directors

Rhea-AI Summary
Immunome, Inc. (Nasdaq: IMNM) appoints Dr. Sandra M. Swain, a seasoned oncology clinical researcher, to its Board of Directors. Dr. Swain's extensive experience and expertise will contribute to advancing the company's pipeline of targeted cancer therapies, including AL102 through Phase 3 and IND filings for IM-1021 and IM-3050.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
management
-
News

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary
Immunome, Inc. (IMNM) announces the presentation of preclinical data for IM-3050, a lead lutetium-177 radioligand therapy targeting fibroblast activation protein (FAP) at the AACR Annual Meeting 2024. The company aims to develop novel cancer therapies with improved therapeutic properties, expecting to submit an Investigational New Drug application in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Rhea-AI Summary
Immunome, Inc. (IMNM) announces transformative year with merger, pipeline advancements, and financial results for 2023. Key highlights include the acquisition of assets, successful financing, and progress in developing targeted cancer therapies. Topline data for Phase 3 RINGSIDE trial of AL102 expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.41%
Tags
acquisition earnings
News

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Rhea-AI Summary
Immunome, Inc. (IMNM) completes the acquisition of AL102 and AL101 from Ayala Pharmaceuticals, focusing on targeted cancer therapies. AL102, a gamma secretase inhibitor, shows promise in treating desmoid tumors, potentially setting a new standard of care. Immunome aims to advance AL102 towards Phase 1 trials, emphasizing its potential efficacy over OGSIVEO™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
acquisition clinical trial
-
News

Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Rhea-AI Summary
Arrayjet partners with Immunome, Inc. (IMNM) to provide its ArrayPlex™ discovery platform for high-throughput screening of targeted cancer therapies. Arrayjet's inkjet technology enables rapid multi-layered assays with two-million data points per cycle, enhancing the discovery of unique binding interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
News

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Rhea-AI Summary
Immunome, Inc. (IMNM) announces Clay Siegall, Ph.D., will present at Leerink Partners 2024 Global Biopharma Conference. The focus is on developing targeted cancer therapies. The presentation will be available via live audio webcast on March 12, 2024, at 4:20 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences
News

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Rhea-AI Summary
Immunome, Inc. (IMNM) announced the participation of its President and CEO in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
News

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Rhea-AI Summary
Immunome, Inc. (IMNM) has entered into an asset purchase agreement with Ayala Pharmaceuticals to acquire AL102 and related drug candidate AL101. Ayala has completed patient enrollment in the Phase 3 RINGSIDE study for AL102 in desmoid tumors. Immunome's Chief Medical Officer is optimistic about the trial's progress and potential, with plans to finalize the acquisition in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
clinical trial
-
News

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
Immunome, Inc. (IMNM) successfully closed a public offering, raising $230.0 million by selling 10,000,000 shares of common stock at $20.00 per share. The underwriters also exercised their option to purchase an additional 1,500,000 shares. The offering was managed by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities. Immunome plans to utilize the proceeds for developing targeted cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
offering
News

Immunome Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary
Immunome, Inc. (IMNM) announces the pricing of an underwritten public offering of 10,000,000 shares of its common stock at $20.00 per share, expecting to raise $200.0 million. The offering includes a 30-day option for additional shares. The offering is set to close on February 16, 2024, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities as joint book-running managers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
offering

FAQ

What is the current stock price of Immunome (IMNM)?

The current stock price of Immunome (IMNM) is $10.97 as of December 20, 2024.

What is the market cap of Immunome (IMNM)?

The market cap of Immunome (IMNM) is approximately 697.8M.

What does Immunome, Inc. specialize in?

Immunome, Inc. specializes in developing innovative cancer immunotherapies by leveraging the human immune system's natural defenses.

What is the core technology platform of Immunome?

The core technology platform of Immunome involves utilizing highly educated immune systems from patients to discover novel antigens and native antibodies.

What are the primary focus areas for Immunome?

Immunome focuses on oncology and infectious diseases, including COVID-19, aiming to revolutionize treatment options.

Can you name some of Immunome's key pipeline assets?

Key pipeline assets include IM-1021, targeting fibroblast activation protein (FAP), and IM-4320.

Where is Immunome, Inc. based?

Immunome, Inc. is based in the United States.

What is the goal of Immunome's development strategy?

Immunome aims to establish a broad pipeline of assets that can be efficiently developed through successive value inflection points.

How does Immunome identify high-affinity antibodies?

Immunome uses a suite of high-content screening technologies to identify specific and high-affinity antibodies.

What distinguishes Immunome's approach to immunotherapy?

Immunome's approach is distinguished by leveraging patients' highly educated immune systems to discover and target novel antigens.

How does Immunome plan to impact cancer treatment?

Immunome plans to impact cancer treatment by developing therapeutics with significant potential to improve patient outcomes.

What recent achievements has Immunome made?

Recent achievements include significant milestones in research, development, and partnerships, further solidifying their leadership in antibody therapeutics.

Stock IMNM logo
Immunome, Inc.

Nasdaq:IMNM

IMNM Rankings

#2824 Ranked by Market Cap
N/A Ranked by Dividends

IMNM Stock Data

697.82M
51.81M
16.99%
83.33%
17.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOTHELL